Larry Goldstein to Follow-Up Studies
This is a "connection" page, showing publications Larry Goldstein has written about Follow-Up Studies.
Connection Strength
0.280
-
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009 Nov; 40(11):3526-31.
Score: 0.052
-
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 05 05; 75(17):2110-2118.
Score: 0.027
-
Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol. 1999 Jun; 17(6):1680-8.
Score: 0.025
-
Reliability and validity of the SA-45: further evidence from a primary care setting. Assessment. 1998 Dec; 5(4):407-19.
Score: 0.024
-
Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke. 2017 12; 48(12):3245-3251.
Score: 0.023
-
Sample size calculations for clinical trials using the NIH Stroke Scale. Stroke. 1994 Aug; 25(8):1700-1.
Score: 0.018
-
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke. 2014 May; 45(5):1429-36.
Score: 0.018
-
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. J Stroke Cerebrovasc Dis. 2014 Apr; 23(4):778-84.
Score: 0.018
-
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.
Score: 0.017
-
Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011 Sep 20; 77(12):1182-90.
Score: 0.015
-
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2010 Mar; 41(3):426-30.
Score: 0.013
-
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007 Dec; 38(12):3198-204.
Score: 0.011
-
Gram-Negative anaerobic endocarditis: two case reports and review of the literature. Eur J Clin Microbiol Infect Dis. 2001 Sep; 20(9):651-4.
Score: 0.007
-
Improved outcome after intestinal transplantation: an 8-year, single-center experience. Transplant Proc. 2000 Sep; 32(6):1233-4.
Score: 0.007
-
Transjugular intrahepatic portosystemic shunts: impact on liver transplantation. Liver Transpl Surg. 1995 Jul; 1(4):229-33.
Score: 0.005